Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label multicenter phase 3 study of Goserelin 10.8 mg Implant HEXAL in advanced hormone-dependent prostate cancer
2008-004351-29Phase 3Completed
- Sponsor
- Hexal AG
- Start
- Nov 2008
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of goserelin in prostate cancer (PCa), sponsored by Hexal AG. Primary endpoint: Testosterone suppression efficacy. Started Nov 2008; status: completed.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-004351-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004351-29.